Medications to Boost White Blood Cell Count
The primary medications used to increase white blood cell counts are colony-stimulating factors (CSFs), specifically filgrastim, pegfilgrastim, tbo-filgrastim, filgrastim-sndz (biosimilar), and lenograstim, which are the standard evidence-based agents for this purpose 1, 2.
Colony-Stimulating Factors (G-CSF)
These are the gold-standard medications for boosting WBC counts, particularly in patients receiving chemotherapy:
Short-Acting G-CSF Agents:
- Filgrastim (Neupogen®) - non-glycosylated G-CSF, administered subcutaneously daily 1, 2
- Lenograstim (Granocyte®) - glycosylated G-CSF with comparable efficacy to filgrastim 2
- Tbo-filgrastim - demonstrated similar safety and efficacy to filgrastim in randomized trials 1
- Filgrastim-sndz - the first FDA-approved biosimilar (March 2015), proven noninferior to filgrastim 1
Long-Acting G-CSF Agent:
- Pegfilgrastim - pegylated filgrastim with extended half-life, allowing once-per-chemotherapy-cycle dosing instead of daily injections 1, 2
All of these G-CSF agents are equally effective at reducing febrile neutropenia risk; choice depends on convenience (pegfilgrastim requires less frequent dosing) and cost considerations 1.
Alternative Oral Agents
While G-CSF is the most effective, several oral leucocyte-increasing drugs exist, though with significantly weaker evidence:
- Leucogen Tablets - showed best WBC-rising effect among oral agents in experimental studies 3
- Berbamine Tablets - demonstrated good WBC, RBC, hemoglobin, and platelet improvement 3
However, these oral agents are substantially less effective than G-CSF and should not be considered first-line therapy 3.
Important Clinical Context
When to Use CSFs:
The major guidelines (ASCO, NCCN, EORTC) recommend G-CSF prophylaxis when the chemotherapy regimen carries >20% risk of febrile neutropenia 1, 2. Risk factors that may warrant CSF use in intermediate-risk cases include:
- Prior chemotherapy
- Abnormal hepatic/renal function
- Low baseline WBC
- Planned delivery of ≥85% chemotherapy dose 2
Common Pitfall:
A significant portion of prescribed G-CSF use occurs outside guideline recommendations - one study found 31% of pegfilgrastim doses were given for low-risk (<10%) chemotherapy regimens where they weren't indicated 4. Avoid reflexive G-CSF prescribing without assessing the actual febrile neutropenia risk of the specific chemotherapy regimen.
Special Indication - Radiation Injury:
For total-body radiation exposure (2-10 Gy), G-CSF or pegfilgrastim should be initiated within 24 hours of exposure to prevent bone marrow failure 1.
Not Recommended for WBC Boosting:
Corticosteroids cause leukocytosis (mean increase 4.84 × 10⁹/L with high doses) but through demargination rather than true WBC production, and should not be used to "boost" WBC counts therapeutically 5.